{"product_id":"metabolic-syndrome-and-cardiovascular-disease-isbn-9781405195751","title":"Metabolic Syndrome and Cardiovascular Disease","description":"\u003cp\u003eTrends indicate that the metabolic syndrome will become the leading risk factor for heart disease. Now more than ever you need an all-in-one reference that provides the tools and practical advice you need to:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e\n\u003cb\u003eIdentify\u003c\/b\u003e at-risk patients\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eExplain\u003c\/b\u003e individual contributing factors\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eAid\u003c\/b\u003e in patient education and motivation\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eDirect\u003c\/b\u003e comprehensive care and\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eChoose\u003c\/b\u003e the most appropriate interventions\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eComprehensively revised to reflect leading-edge research and now organized to facilitate easy access to essential information and clinically-relevant guidance\u003ci\u003e, \u003cb\u003eMetabolic Syndrome and Cardiovascular Disease, 2e\u003c\/b\u003e\u003c\/i\u003e offers this and more. Not only will you receive a solid understanding of the pathophysiology underlying the metabolic syndrome and cardiovascular disease \u003ci\u003ebut also\u003c\/i\u003e the rationale for today’s most effective treatments.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eWhat’s new?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFilled with timely new content, this updated edition covers:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eNew discoveries that have changed our understanding of the pathogenesis and interrelationship of metabolic syndrome, cardiovascular disease (CHD), and type 2 diabetes mellitus (DM)\u003c\/li\u003e \u003cli\u003eThe relevance of mitochondria and telomeres\u003c\/li\u003e \u003cli\u003eSleep and its impact on cardiometabolic health\u003c\/li\u003e \u003cli\u003eThe pivotal interplay between insulin and forkhead transcriptionfactors\u003c\/li\u003e \u003cli\u003eCalorie restriction research\u003c\/li\u003e \u003cli\u003eBariatric surgery experiences and outcomes\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn addition, each chapter includes essential information on comorbidities, interventions, and pharmacotherapeutic options – an exclusive feature found only in the second edition!\u003c\/p\u003e  \u003cp\u003ePreface  viii\u003c\/p\u003e \u003cp\u003eList of Abbreviations  ix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Metabolic Syndrome: A Relevant Concept?  1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Mitochondria  3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBackground  3\u003c\/p\u003e \u003cp\u003eCellular respiration  6\u003c\/p\u003e \u003cp\u003eModulation of mitochondrial metabolic activity  9\u003c\/p\u003e \u003cp\u003eFactors that affect mitochondrial number and activity  10\u003c\/p\u003e \u003cp\u003ePeroxisome proliferator–activated receptor gamma coactivator-1  11\u003c\/p\u003e \u003cp\u003eMitochondrial production of prooxidant species  12\u003c\/p\u003e \u003cp\u003eMitochondria and nitric oxide  15\u003c\/p\u003e \u003cp\u003eMitochondrial calcium homeostasis  17\u003c\/p\u003e \u003cp\u003eThe mitochondrial permeability transition   18\u003c\/p\u003e \u003cp\u003eApoptosis   22\u003c\/p\u003e \u003cp\u003eCauses for mitochondrial dysfunction   22\u003c\/p\u003e \u003cp\u003eImplications of mitochondrial dysfunction   27\u003c\/p\u003e \u003cp\u003eMitochondrial dysfunction and cardiovascular disease   27\u003c\/p\u003e \u003cp\u003eMitochondrial dysfunction and metabolic disease   29\u003c\/p\u003e \u003cp\u003eConclusion   32\u003c\/p\u003e \u003cp\u003eBibliography   34\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Telomeres   40\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTelomere structure   40\u003c\/p\u003e \u003cp\u003eTelomere function   41\u003c\/p\u003e \u003cp\u003eTelomere shortening   41\u003c\/p\u003e \u003cp\u003eTelomere dysfunction   42\u003c\/p\u003e \u003cp\u003ePhysiologic age   42\u003c\/p\u003e \u003cp\u003eGender differences   43\u003c\/p\u003e \u003cp\u003eTelomerase   43\u003c\/p\u003e \u003cp\u003eCell senescence and apoptosis   46\u003c\/p\u003e \u003cp\u003eTelomeres in aging   49\u003c\/p\u003e \u003cp\u003eRisk factors for cardiometabolic disease   51\u003c\/p\u003e \u003cp\u003eTelomeres  senescence  and chronic disease   54\u003c\/p\u003e \u003cp\u003eCardiovascular disease   54\u003c\/p\u003e \u003cp\u003eInsulin resistance and type 2 DM   57\u003c\/p\u003e \u003cp\u003eConclusion   58\u003c\/p\u003e \u003cp\u003eBibliography   60\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The FoxO Transcription Factors and Sirtuins   64\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eForkhead transcription factors   64\u003c\/p\u003e \u003cp\u003eFunctions of FoxO   68\u003c\/p\u003e \u003cp\u003eCardiovascular forkhead effects   70\u003c\/p\u003e \u003cp\u003eMetabolic forkhead effects   72\u003c\/p\u003e \u003cp\u003eHistone acetylation and deacetylation   75\u003c\/p\u003e \u003cp\u003eSirtuin deacetylases   76\u003c\/p\u003e \u003cp\u003eSirtuin regulation   78\u003c\/p\u003e \u003cp\u003eAntiinflammatory  cardiovascular  and myocyte sirtuin effects   80\u003c\/p\u003e \u003cp\u003eSirtuin effects on metabolism   81\u003c\/p\u003e \u003cp\u003eSirtuins and cell longevity   83\u003c\/p\u003e \u003cp\u003eForkhead deregulation and insulin resistance   85\u003c\/p\u003e \u003cp\u003eParadoxical effect of nutrition versus stress on cell death suppression   87\u003c\/p\u003e \u003cp\u003eConclusion   89\u003c\/p\u003e \u003cp\u003eBibliography   90\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Insulin and Insulin-Like Growth Factor   96\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAnabolism and catabolism   96\u003c\/p\u003e \u003cp\u003eControl of plasma glucose   96\u003c\/p\u003e \u003cp\u003eInsulin   97\u003c\/p\u003e \u003cp\u003eInsulin receptor location   98\u003c\/p\u003e \u003cp\u003eMetabolic insulin signaling   101\u003c\/p\u003e \u003cp\u003eInsulin-mediated glucose uptake   103\u003c\/p\u003e \u003cp\u003eNutrient storage and metabolism   104\u003c\/p\u003e \u003cp\u003eVascular and antiinflammatory effects   106\u003c\/p\u003e \u003cp\u003eMitogenic action   107\u003c\/p\u003e \u003cp\u003eInsulin-like growth factor   108\u003c\/p\u003e \u003cp\u003eInsulin and IGF impact on cell longevity   111\u003c\/p\u003e \u003cp\u003eAmylin   113\u003c\/p\u003e \u003cp\u003eGlucagon   113\u003c\/p\u003e \u003cp\u003eConclusion   113\u003c\/p\u003e \u003cp\u003eBibliography  114\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Oxidative Stress   120\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFree radicals   120\u003c\/p\u003e \u003cp\u003eOxidases   120\u003c\/p\u003e \u003cp\u003eSources for free radicals   123\u003c\/p\u003e \u003cp\u003eEndogenous antioxidants   124\u003c\/p\u003e \u003cp\u003ePhysiologic functions of oxidative stress   126\u003c\/p\u003e \u003cp\u003eMechanisms of oxidative damage   127\u003c\/p\u003e \u003cp\u003eCellular stress-sensitive pathways   127\u003c\/p\u003e \u003cp\u003eCellular targets of oxidative stress   128\u003c\/p\u003e \u003cp\u003eOxidative stress-related diseases   129\u003c\/p\u003e \u003cp\u003eEndothelial dysfunction with oxidative stress   129\u003c\/p\u003e \u003cp\u003eCardiovascular disease   130\u003c\/p\u003e \u003cp\u003eInsulin resistance and type 2 DM   131\u003c\/p\u003e \u003cp\u003eConclusion   133\u003c\/p\u003e \u003cp\u003eBibliography   134\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Mental Stress   139\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eStress responses   139\u003c\/p\u003e \u003cp\u003eCentral stress pathways   139\u003c\/p\u003e \u003cp\u003ePeripheral stress pathways   140\u003c\/p\u003e \u003cp\u003eFight-flight-fright responses to acute stress   142\u003c\/p\u003e \u003cp\u003eSequelae of sustained passive stress   142\u003c\/p\u003e \u003cp\u003eInflammatory effects of stress pathways   143\u003c\/p\u003e \u003cp\u003eVascular and lipoprotein effects of\u003c\/p\u003e \u003cp\u003estress pathways   143\u003c\/p\u003e \u003cp\u003eStress impact on body weight   146\u003c\/p\u003e \u003cp\u003eMetabolic effects of stress pathways   146\u003c\/p\u003e \u003cp\u003eDepression and other mood disturbances   149\u003c\/p\u003e \u003cp\u003eConclusion   152\u003c\/p\u003e \u003cp\u003eBibliography   153\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Sleep   159\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eStages of sleep   159\u003c\/p\u003e \u003cp\u003eCardiovascular parameters during normal sleep   160\u003c\/p\u003e \u003cp\u003eFunction of sleep   161\u003c\/p\u003e \u003cp\u003eSleep duration   164\u003c\/p\u003e \u003cp\u003eCircadian rhythm   165\u003c\/p\u003e \u003cp\u003eExamples of circadian regulation   166\u003c\/p\u003e \u003cp\u003eNeurohormonal modulation of wakefulness   168\u003c\/p\u003e \u003cp\u003eNeurohormonal modulation of sleep   170\u003c\/p\u003e \u003cp\u003eSleep–arousal transitions   172\u003c\/p\u003e \u003cp\u003eSleep deficit   174\u003c\/p\u003e \u003cp\u003ePathophysiologic effects of sleep debt   175\u003c\/p\u003e \u003cp\u003eSleep debt and risk of cardiometabolic disorder   177\u003c\/p\u003e \u003cp\u003eSleep disorders   179\u003c\/p\u003e \u003cp\u003eConclusion   182\u003c\/p\u003e \u003cp\u003eBibliography   183\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Inflammation   192\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eImmune responses   192\u003c\/p\u003e \u003cp\u003eSelected participants in the inflammatory response   193\u003c\/p\u003e \u003cp\u003eC-reactive protein   198\u003c\/p\u003e \u003cp\u003eThe renin–angiotensin–aldosterone system and inflammation   199\u003c\/p\u003e \u003cp\u003eInflammation and chronic diseases   202\u003c\/p\u003e \u003cp\u003eInflammation  endothelial and vascular dysfunction   202\u003c\/p\u003e \u003cp\u003eInflammation and atherosclerosis   205\u003c\/p\u003e \u003cp\u003eAcute inflammation  carbohydrate metabolism  and dyslipidemia   210\u003c\/p\u003e \u003cp\u003eChronic inflammation and the metabolic syndrome   213\u003c\/p\u003e \u003cp\u003eCauses for systemic inflammation   215\u003c\/p\u003e \u003cp\u003eConclusion   218\u003c\/p\u003e \u003cp\u003eBibliography   219\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Adipose Tissue and Overweight   228\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEnergy storage   228\u003c\/p\u003e \u003cp\u003eDiverse fat depots   230\u003c\/p\u003e \u003cp\u003eAdipose tissue as immune organ   234\u003c\/p\u003e \u003cp\u003eAdipose tissue as endocrine organ   236\u003c\/p\u003e \u003cp\u003eAdipokines with beneficial cardiometabolic effect   237\u003c\/p\u003e \u003cp\u003eAdipokines with detrimental cardiometabolic effect   244\u003c\/p\u003e \u003cp\u003eObesity comorbidities and cardiovascular disease   250\u003c\/p\u003e \u003cp\u003eObesity  insulin resistance  and diabetes   252\u003c\/p\u003e \u003cp\u003eConclusion   254\u003c\/p\u003e \u003cp\u003eBibliography   255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Weight Loss and Diet   266\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHomeostatic responses to weight gain and weight loss   266\u003c\/p\u003e \u003cp\u003eAdipose weight loss effects   267\u003c\/p\u003e \u003cp\u003eAntiinflammatory  vasculoprotective  and metabolic effects of weight loss   267\u003c\/p\u003e \u003cp\u003eDietary intervention for weight loss   269\u003c\/p\u003e \u003cp\u003eCalorie restriction   270\u003c\/p\u003e \u003cp\u003eSurgical intervention   277\u003c\/p\u003e \u003cp\u003eDiet   279\u003c\/p\u003e \u003cp\u003eExercise as adjunct to weight loss   289\u003c\/p\u003e \u003cp\u003eConclusion   289\u003c\/p\u003e \u003cp\u003eBibliography   291\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Skeletal Muscle and Exercise   303\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMyocyte structure and function   303\u003c\/p\u003e \u003cp\u003eMetabolic adaptations in skeletal muscle   305\u003c\/p\u003e \u003cp\u003eEnergy sensors   311\u003c\/p\u003e \u003cp\u003eSkeletal muscle in inflammation   317\u003c\/p\u003e \u003cp\u003eSkeletal muscle in insulin resistance   318\u003c\/p\u003e \u003cp\u003eExercise effect on inflammation and oxidative stress   320\u003c\/p\u003e \u003cp\u003eExercise effect on metabolism in obesity  322\u003c\/p\u003e \u003cp\u003eExercise effect and cardiovascular health   322\u003c\/p\u003e \u003cp\u003eExercise and insulin resistance   325\u003c\/p\u003e \u003cp\u003eExercise and mortality   328\u003c\/p\u003e \u003cp\u003eExercise recommendation   331\u003c\/p\u003e \u003cp\u003eConclusion   332\u003c\/p\u003e \u003cp\u003eBibliography   334\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Lipids  Atherogenic Dyslipidemia  and Therapy   347\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eApolipoproteins   347\u003c\/p\u003e \u003cp\u003eLipoproteins   347\u003c\/p\u003e \u003cp\u003eApo A-containing lipoproteins   348\u003c\/p\u003e \u003cp\u003eApo B-containing lipoproteins   355\u003c\/p\u003e \u003cp\u003eApolipoproteins C  D  and E   360\u003c\/p\u003e \u003cp\u003eThe triglyceride lipase family   360\u003c\/p\u003e \u003cp\u003eThe normal metabolism of free fatty acids   363\u003c\/p\u003e \u003cp\u003eInflammation and hepatic insulin resistance   365\u003c\/p\u003e \u003cp\u003eAtherogenic dyslipidemia in insulin resistance   369\u003c\/p\u003e \u003cp\u003eLipid-lowering therapy   372\u003c\/p\u003e \u003cp\u003eThe HMG CoA reductase inhibitors   374\u003c\/p\u003e \u003cp\u003eNicotinic acid   387\u003c\/p\u003e \u003cp\u003eThe fibric acid derivatives   388\u003c\/p\u003e \u003cp\u003eBile acid sequestrants   391\u003c\/p\u003e \u003cp\u003eEzetimibe   391\u003c\/p\u003e \u003cp\u003eCETP inhibition   391\u003c\/p\u003e \u003cp\u003eConclusion   392\u003c\/p\u003e \u003cp\u003eBibliography   393\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 The Endothelium  Cardiovascular Disease  and Therapy   409\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEndothelial function  409\u003c\/p\u003e \u003cp\u003eNitric oxide synthase and eNOS  409\u003c\/p\u003e \u003cp\u003eEndothelial NO synthesis  410\u003c\/p\u003e \u003cp\u003eSpecific enhancers of NO synthesis   413\u003c\/p\u003e \u003cp\u003eFunctions of nitric oxide   415\u003c\/p\u003e \u003cp\u003eShear stress and vascular function   418\u003c\/p\u003e \u003cp\u003eMechanisms of endothelial dysfunction   420\u003c\/p\u003e \u003cp\u003eInsulin  insulin resistance  and endothelial dysfunction   424\u003c\/p\u003e \u003cp\u003eImplications of endothelial dysfunction   428\u003c\/p\u003e \u003cp\u003eAssessment of endothelial function   430\u003c\/p\u003e \u003cp\u003eHypertension   432\u003c\/p\u003e \u003cp\u003eCardiomyopathy   434\u003c\/p\u003e \u003cp\u003eCoronary and peripheral vascular disease   440\u003c\/p\u003e \u003cp\u003ePharmacologic antagonism of the  renin–angiotensin–aldosterone system and endothelin-1   443\u003c\/p\u003e \u003cp\u003eBeta-adrenergic blockade   448\u003c\/p\u003e \u003cp\u003ePhosphodiesterase-5 inhibitors  449\u003c\/p\u003e \u003cp\u003eConclusion   450\u003c\/p\u003e \u003cp\u003eBibliography   451\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Insulin Resistance  Metabolic Syndrome  and Therapy   468\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDiagnostic criteria for the metabolic syndrome   468\u003c\/p\u003e \u003cp\u003ePrevalence of the metabolic syndrome   470\u003c\/p\u003e \u003cp\u003eInsulin resistance   470\u003c\/p\u003e \u003cp\u003eCauses of insulin resistance   474\u003c\/p\u003e \u003cp\u003ePathways toward insulin resistance   476\u003c\/p\u003e \u003cp\u003ePharmacologic therapy to improve insulin sensitivity   480\u003c\/p\u003e \u003cp\u003eConclusion   483\u003c\/p\u003e \u003cp\u003eBibliography   484\u003c\/p\u003e \u003cp\u003eIndex   491\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eT. Barry Levine\u003c\/strong\u003e, MD, FACC, is Chief Medical Officer, A.B.L.E. Medical Consulting. He is Professor of Medicine at Drexel University College of Medicine in Philadelphia, PA. Dr. Levine is a Fellow of the American College of Cardiology, a member of the Scientific Advisory Board of the International Academy of Cardiology, and a board member of the Tracleer International Scientific Advisory Board. In addition, he is a member of the American Federation for Clinical Research, the American Heart Association, the International Society for Heart and Lung Transplantation, the American College of Chest Physicians, and the Heart Failure Society of America. Dr. Levine has been recognized by his peers in \"Best Doctors in America\" and \"Top Docs in Pittsburgh\". Dr. Levine has participated in numerous clinical trials, authored many articles (138), and created a variety of media presentations on heart failure, hypertension, dyslipidemia, and metabolic syndrome. He along with Dr. Arlene B. Levine has written \"A Patient's Guide to Heart Failure\" and has authored a textbook, \"Metabolic Syndrome and Cardiovascular Disease\". \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eArlene Bradley Levine\u003c\/strong\u003e, MD, FACC, is CEO, A.B.L.E. Medical Consulting. She is Assistant Professor of Medicine at Michigan State University and? is board-certified in Internal Medicine and Cardiovascular Disease. Dr. Levine is a Fellow of the American College of Cardiology. She is a member of the American Heart Association, the International Society for Heart and Lung Transplantation, the American College of Chest Physicians, and the Heart Failure Society of America. Dr. Levine has authored 45 articles, and has been recognized by her peers in \"Best Doctors in America\" and \"Top Docs in Pittsburgh\".   \u003c\/p\u003e\u003cp\u003eTrends indicate that the metabolic syndrome will become the leading risk factor for heart disease. Now more than ever you need an all-in-one reference that provides the tools and practical advice you need to:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e\n\u003cb\u003eIdentify\u003c\/b\u003e at-risk patients\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eExplain\u003c\/b\u003e individual contributing factors\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eAid\u003c\/b\u003e in patient education and motivation\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eDirect\u003c\/b\u003e comprehensive care and\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eChoose\u003c\/b\u003e the most appropriate interventions\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eComprehensively revised to reflect leading-edge research and now organized to facilitate easy access to essential information and clinically-relevant guidance\u003ci\u003e, \u003cb\u003eMetabolic Syndrome and Cardiovascular Disease, 2e\u003c\/b\u003e\u003c\/i\u003e offers this and more. Not only will you receive a solid understanding of the pathophysiology underlying the metabolic syndrome and cardiovascular disease \u003ci\u003ebut also\u003c\/i\u003e the rationale for today’s most effective treatments.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eWhat’s new?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFilled with timely new content, this updated edition covers:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eNew discoveries that have changed our understanding of the pathogenesis and interrelationship of metabolic syndrome, cardiovascular disease (CHD), and type 2 diabetes mellitus (DM)\u003c\/li\u003e \u003cli\u003eThe relevance of mitochondria and telomeres\u003c\/li\u003e \u003cli\u003eSleep and its impact on cardiometabolic health\u003c\/li\u003e \u003cli\u003eThe pivotal interplay between insulin and forkhead transcriptionfactors\u003c\/li\u003e \u003cli\u003eCalorie restriction research\u003c\/li\u003e \u003cli\u003eBariatric surgery experiences and outcomes\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn addition, each chapter includes essential information on comorbidities, interventions, and pharmacotherapeutic options – an exclusive feature found only in the second edition!\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989610283237,"sku":"NP9781405195751","price":153.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405195751.jpg?v=1761784800","url":"https:\/\/k12savings.com\/es\/products\/metabolic-syndrome-and-cardiovascular-disease-isbn-9781405195751","provider":"K12savings","version":"1.0","type":"link"}